Results 241 to 250 of about 12,230 (281)

The protective effects of trimetazidine against ovary ischemia–reperfusion injury via the TLR4/Nf‐kB signal pathway

Journal of biochemical and molecular toxicology, 2022
Late diagnosis and treatment of ovarian ischemia can lead to worsening of ischemia, irreversible damage to ovarian functions and infertility. In this process, there is no approved medical treatment that can reduce the negative effects of ischemia and ...
Aykut Ozturk, A. Topçu, Esra Deniz, Seda Duman Ozturk, M. Arpa, Eda Kutlu Yilmaz   +5 more
semanticscholar   +1 more source

Doping control analysis of trimetazidine in dried blood spot.

Drug Testing and Analysis, 2022
Dried blood spot (DBS) analysis has been an inherent part of sports drug testing through the technological advancements of the past decade. Trimetazidine, a non-threshold banned substance, is excreted into urine after a dose of the permitted drug ...
M. Okano, Asami Miyamoto, Masanori Ota, Shinji Kageyama, Mitsuhiko Sato   +4 more
semanticscholar   +1 more source

Trimetazidine not beneficial after PCI

Nature Reviews Cardiology, 2020
Findings from the ATPCI trial show that trimetazidine is safe but not protective against angina and cardiac events in the long term after percutaneous coronary intervention.
openaire   +2 more sources

Trimetazidine and parkinsonism: A prospective study

Parkinsonism & Related Disorders, 2019
Although trimetazidine may induce parkinsonian symptoms in some patients, no systematic characterization has been reported on parkinsonism occurring during trimetazidine treatment since the first case reports.To systematically investigate parkinsonism occurring during trimetazidine use.Thirty-three consecutive patients on trimetazidine treatment with ...
Dávid Pintér, Márton Kovács, Márk Harmat, Annamária Juhász, József Janszky, Norbert Kovács   +5 more
openaire   +3 more sources

Antinociceptive effect of ranolazine and trimetazidine

Expert Review of Cardiovascular Therapy, 2021
Background:Ranolazine and trimetazidine are piperazine derivatives used in antianginal therapy. There are data on the use of these drugs in the treatment of neuropathic pain. In this study, it was aimed to evaluate the antinociceptive effects of ranolazine and trimetazidine.Methods: Sixty patients who were started on trimetazidine or ranolazine ...
openaire   +2 more sources

Trimetazidine: stability indicating RPLC assay method

Journal of Pharmaceutical and Biomedical Analysis, 2001
An accurate, specific and reproducible reversed phase liquid chromatographic method for the determination of trimetazidine hydrochloride in presence of its degradation products is reported. The mobile phase consisted of water-acetonitrile-triethylamine (90:10:0.1, v/v/v) adjusted with o-phosphoric acid to a pH of 3.3. Chromatography was performed using
S O, Thoppil, P D, Amin
openaire   +2 more sources

Trimetazidine for stable angina pectoris

Expert Opinion on Pharmacotherapy, 2001
Stable angina pectoris, a symptom of coronary heart disease (CHD), manifests as stress-induced ischaemic episodes resulting in severe chest pain. Therapeutic aims are to improve quality of life by decreasing anginal attacks and to prevent myocardial infarction (MI) and death.
openaire   +2 more sources

Trimetazidine increases phosppholipid turnover in ventricular myocyte

Molecular and Cellular Biochemistry, 1997
Trimetazidine (TMZ) is an anti-ischemic compound devoid of hemodynamic effects. It was recently suggested to induce cardiomyocyte protection by a mechanism involving lipid metabolism. The effects of TMZ were evaluated in rats on cardiac lipid composition, and in cultured rat cardiomyocytes on phospholipid metabolism.
Sentex, Emmanuelle, Sergiel, J.P., Lucien, A., Grynberg, Alain   +3 more
openaire   +3 more sources

Does trimetazidine act as antioxidant?

Bulletin of Experimental Biology and Medicine, 1998
Trimetazidine is 2-fold inferior to probucol in antioxidant activity measured using the model of copper-induced free radical oxidation of human plasma lipoproteins. EPR-spectroscopy shows that trimetazidine forms no free-radical intermediates in the presence of generated lipid alkoxyl or hydroxyl radicals, while probucol under these conditions forms ...
A. K. Tikhaze, V. Z. Lankin, S. V. Kolycheva, G. G. Konovalova, K. B. Shumaev, A. I. Kozachenko, S. M. Gurevich, E. A. Zharova, L. D. Smirnov   +8 more
openaire   +1 more source

Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury

Naunyn-Schmiedeberg's Archives of Pharmacology, 2023
M. Farzaei, Fatemeh Ramezani-Aliakbari, Maryam Ramezani-Aliakbari, M. Zarei, A. Komaki, S. Shahidi, A. Sarihi, I. Salehi   +7 more
semanticscholar   +1 more source